Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM
JCO Precision Oncology · 2023
DOI: 10.1200/po.23.00015 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2023. Verfasst von Anna-Elisa Heipertz und 25 weiteren Autor:innen. Beteiligte Einrichtung: Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Carcinoma. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
PURPOSE INFORM is an international pediatric precision oncology registry, prospectively collecting molecular and clinical data of children with recurrent, progressive, or very high-risk malignancies. We have previously identified a subgroup of patients with improved outcomes on the basis of molecular profiling. The present analysis systematically investigates progression-free survival (PFS) and overall survival (OS) of patients receiving matching targeted treatment (MTT) with the most frequently applied drug classes and its correlation with underlying molecular alterations. METHODS A cohort of 519 patients with relapsed or refractory high-risk malignancies who had completed a follow-up of at least 2 years or shorter in the case of death or loss to follow-up was analyzed. Survival times were compared using the log-rank test. RESULTS MTT with anaplastic lymphoma kinase (ALK), neurotrophic tyrosine receptor kinase (NTRK), and B-RAF kinase (BRAF) inhibitors showed significantly improved PFS ( P = .012) and OS ( P = .036) in comparison with conventional treatment or no treatment. However, analysis of the four most commonly applied MTT groups, mitogen-activated protein kinase (MEK- n = 19), cyclin-dependent kinase (CDK- n = 23), other kinase (n = 62), and mammalian-target of rapamycin (mTOR- n = 20) inhibitors, did not reveal differences in PFS or OS compared with conventional treatment or no treatment in patients with similar molecular pathway alterations. We did not observe differences in the type of pathway alterations (eg, copy number alterations, single-nucleotide variants, InDels, gene fusions) addressed by MTT. CONCLUSION Patients with respective molecular alterations benefit from treatment with ALK, NTRK, and BRAF inhibitors as previously described. No survival benefit was observed with MTT for mutations in the MEK, CDK, other kinase, or mTOR signaling pathways. The noninterventional character of a registry has to be taken into account when interpreting these data and underlines the need for innovative interventional biomarker–driven clinical trials in pediatric oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
- Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Pediatric Oncology, Hematology, Immunology and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany.
- German Cancer Consortium (DKTK), Heidelberg, Germany.
- Heidelberg Medical Faculty, University of Heidelberg, Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), Heidelberg, Germany.
ORCID-Profile: Anna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, Till Milde, Cecilia Zuliani, Caroline Hutter, Olli Lohi, Antonis Kattamis, Anna Nilsson, Karin P S Langenberg, Bianca Goemans, C Michel Zwaan, Natalie Jäger, Uta Dirksen, David T W Jones, Annette Kopp-Schneider, Cornelis M van Tilburg
Zitieren
APA
Heipertz, A. E., Pajtler, K. W., Pfaff, E., Schramm, K., Blattner-Johnson, M., Milde, T., Jones, B. C., Zuliani, C., Hutter, C., Lohi, O., Kattamis, A., Dachowska-Kalwak, I., Nilsson, A., Gerber, N. U., Langenberg, K. P. S., Goemans, B., Zwaan, C. M., Molenaar, J. J., Jäger, N., …, & van Tilburg, C. M. (2023). Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO Precision Oncology. https://doi.org/10.1200/po.23.00015
Vancouver
Heipertz AE, Pajtler KW, Pfaff E, Schramm K, Blattner-Johnson M, Milde T, et al. Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO Precision Oncology. 2023. doi:10.1200/po.23.00015
BibTeX
@article{Heipertz2023,
author = {Heipertz, Anna-Elisa and Pajtler, Kristian W and Pfaff, Elke and Schramm, Kathrin and Blattner-Johnson, Mirjam and Milde, Till and Jones, Barbara C and Zuliani, Cecilia and Hutter, Caroline and Lohi, Olli and Kattamis, Antonis and Dachowska-Kalwak, Iwona and Nilsson, Anna and Gerber, Nicolas U and Langenberg, Karin P S and Goemans, Bianca and Zwaan, C Michel and Molenaar, Jan J and Jäger, Natalie and Dirksen, Uta and Witt, Ruth and Pfister, Stefan M and Jones, David T W and Kopp-Schneider, Annette and Witt, Olaf and van Tilburg, Cornelis M},
title = {Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM},
journal = {JCO Precision Oncology},
year = {2023},
doi = {10.1200/po.23.00015}
}
EUVIMED